NCT02873962 2026-04-01
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Dana-Farber Cancer Institute
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
pharmaand GmbH
Royal Marsden NHS Foundation Trust
Brown University
Academic and Community Cancer Research United